A bionanotech designer and maker of nanostructured chips, devices and systems for fast, comprehensive, and low-cost analysis of native state genomic, epigenomic and proteomic information with sensitivity at the single cell / single molecule level.
The company's technology is based on the large scale production of nanometric particles known as VLPs (virus like particles). The most advanced application of this technology is the production of viral vector derived vaccines for human and animal health.
BioPAL provides products and methods to measure in vivo organ function and to track compounds-of-interest in in vivo systems. Products developed for neutron activation technology include nanocolloids for labeling, tracking and quantifying cells in in vivo models.
Through its diagnostic program, Biophage is developing a biosensor using an innovative nanotechnology. These nanosensors are based on impedance spectroscopy, an enabling technology that can detect and quantify microbial pathogens in real-time. The unique nanosensors will be built from various proprietary technologies already developed by Biophage (biocapture molecule: phages and antibodies) and by the Biotechnology Research Institute-NRC (signal generation and detection).
The company has a polymer micro-system technology platform comprising core intellectual property in the areas of polymer multilevel micro- and nano-replication, plastic micro-fluidic chip fabrication and photonics integration, to provide unique products for point-of-use analytical applications.
Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases. The company is pioneering an integrative way to discover molecular entities with new mechanisms of action purposely designed for our proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together they can make medicines more targeted, more effective and more tolerable.
Calevia aims to harness the power of molecular targeting technologies and the heat-generation capacity of MesoGraf Xide, a photo-responsive graphene material, to create bio-conjugates designed to home-in on - and destroy - cancer cells in a non-invasive, non-pharmacological and efficient manner.
A leading provider of cutting-edge technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper has compiled numerous best-in-class solutions and is aggressively innovating new technologies to bridge the gaps that exist in bringing in vitro assays to in vivo results and ultimately into cures for human disease.
Camurus specializes in the development of pharmaceuticals based on advanced and effective innovative nanoscale drug delivery systems that optimize the bioavailability and therapeutic performance of a wide range of difficult substances, including: peptides, proteins, and insoluble small molecules.
A a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. The company's sensors are designed and manufactured using microelectromechanical systems, or MEMS, technology, which enables the fabrication of millimeter-scale devices with internal features in the nanometer to micrometer range.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
Celsense is a biotechnology company offering novel MRI contrast agents (fluorochemical nanoparticles) that allow scientists and clinicians to monitor the position and quantity of transplanted cells non-invasively in vivo.
Commercializes a nano and micron sized ceramic spheres technology that provides encapsulation and controlled release of active molecules for a variety of applications including drug delivery, cosmeceuticals and speciality chemicals.